The calcipotriene 0.005%/betamethasone dipropionate 0.064% foam formulation (ENSTILAR ® (formerly LEO 90100), LEO Pharma A/S, Ballerup, Denmark) was approved in October 2015 by the US Food and Drug Administration.
The calcipotriene 0.005%/betamethasone dipropionate 0.064% foam was applied once daily for four weeks. The foam formulation was approved in October 2015 by the US Food and Drug Administration.